抗肝癌中药物质基础研究进展

中图分类号：R979.1 文献标识码：A 文章编号：1001-8751（2025）03-0145-09

AdvancesintheBasicResearchofTraditionalChineseMedicine forAnti-LiverCancer

LiuLu-yang1，WuSi-yang1，ZhaoLi-feng1，YuXin1，ChengXue-haol，Huang Zhi-shan12，Yuan Zhengl，LiYing-feil （1 Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences，Beijing 100700; 2BeijingUniversity of Traditional Chinese Medicine， Beijing 102488）

Abstract： Primary liver cancer poses a serious threat to human health，and traditional Chinese medicine （TCM） has a long historyinthe preventionand treatment of primary livercancer.In recent years，its therapeutic mechanisms havealso atracted atention.Inaddition todiscussing the material basis of Chinese medicine substances by mechanismofaction，such asaffecting thecellcycle，inducingapoptosis and autophagy，inhibitingangiogenesis and metastasis，microenvironment regeneration，DNA methylation，and regulating immuneresponses，this article summarizes common Chinese medicine substances used in the treatment of primary liver cancer，such as matrine， berberine，and curcumin，among others.Traditional Chinese medicine has a protective and conditioning effect on patients with long-term primary liver cancer. Promoting research on Chinese medicine and its mechanisms of action is crucial for the treatment of primary liver cancer.The purposeof this study is to supportTCMresearch and clinical application while offering a scientific foundation for its use in the treatment of primary liver cancer.

Key words： traditional Chinese medicine；liver cancer；material basis;mechanism of action;acutophagy angiogenesis Inhibition

原发性肝癌（Primary liver cancer，PLC），亦称肝细胞癌（Hepatocellularcarcinoma，HCC），在全球恶性肿瘤中占有一席之地，其中中国过去曾占全球肝癌负担的一半以上，但最近观察到全国性肝癌发病率的下降[I。（剩余21368字）